Pacific Biosciences of California, Inc. (PACB)

NMS – Real vaqt narxi. Valyuta: USD

1.28

-0.07 (-5.54%)

Yopilishda: May 12, 2026, 4:00 PM EDT

1.28

0.00 (0.00%)

Bozor oldidan: May 13, 2026, 4:40 AM EDT

08.05.2026

Pacific Biosciences of California Q1 Earnings Call Highlights

Pacific Biosciences of California NASDAQ: PACB reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument performance amid ongoing pressure in academic and government funding, particularly in the U.S.

08.05.2026

PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down

PacBio beats Q1 earnings estimates as consumables growth and cost cuts offset flat revenue and a weaker gross margin.

08.05.2026

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

07.05.2026

Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.

07.05.2026

PacBio Announces First Quarter 2026 Financial Results

MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.

05.05.2026

PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?

PACB heads into Q1 earnings with strong consumables momentum, but muted academic demand and macro pressures cloud near-term visibility.

22.04.2026

Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.71, marking a -1.16% move from the previous day.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

PacBio Announces First Quarter 2026 Financial Results

MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.

21.04.2026

PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing

Expands access to streamlined genomic data analysis across the PacBio partner ecosystem Expands access to streamlined genomic data analysis across the PacBio partner ecosystem

15.04.2026

PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples

New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research

18.03.2026

Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative

PacBio's Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics PacBio's Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics

Pacific Biosciences of California, Inc. (PACB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pacific Biosciences of California, Inc. (PACB)

Pacific Biosciences of California Q1 Earnings Call Highlights

PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates

PacBio Announces First Quarter 2026 Financial Results

PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?

Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors

Videolar

No Data

Press-relizlar

PacBio Announces First Quarter 2026 Financial Results

PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing

PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples

Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative

Pacific Biosciences of California Q1 Earnings Call Highlights

PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates

PacBio Announces First Quarter 2026 Financial Results

PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?

Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors

Videolar

No Data

Press-relizlar

PacBio Announces First Quarter 2026 Financial Results

PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing

PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples

Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative

Search stocks

Pacific Biosciences of California, Inc. (PACB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pacific Biosciences of California, Inc. (PACB)

Pacific Biosciences of California Q1 Earnings Call Highlights

PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates

PacBio Announces First Quarter 2026 Financial Results

PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?

Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors

Videolar

No Data

Press-relizlar

PacBio Announces First Quarter 2026 Financial Results

PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing

PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples

Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative

Pacific Biosciences of California Q1 Earnings Call Highlights

PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates

PacBio Announces First Quarter 2026 Financial Results

PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?

Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors

Videolar

No Data

Press-relizlar

PacBio Announces First Quarter 2026 Financial Results

PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing

PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples

Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative